Article
Genome-wide association study of survival in patients with pancreatic adenocarcinoma.
Gut - 1 Jan 2014
Wu Chen, Kraft Peter, Stolzenberg-Solomon Rachael, Steplowski Emily, Brotzman Michelle, Xu Mousheng, Mudgal Poorva, Amundadottir Laufey, Arslan Alan A, Bueno-de-Mesquita H Bas, Gross Myron, Helzlsouer Kathy, Jacobs Eric J, Kooperberg Charles, Petersen Gloria M, Zheng Wei, Albanes Demetrius, Boutron-Ruault Marie-Christine, Buring Julie E, Canzian Federico, Cao Guangwen, Duell Eric J, Elena Joanne W, Gaziano J Michael, Giovannucci Edward L, Hallmans Goran, Hutchinson Amy, Hunter David J, Jenab Mazda, Jiang Guoliang, Khaw Kay-Tee, LaCroix Andrea, Li Zhaoshen, Mendelsohn Julie B, Panico Salvatore, Patel Alpa V, Qian Zhi Rong, Riboli Elio, Sesso Howard, Shen Hongbing, Shu Xiao-Ou, Tjonneland Anne, Tobias Geoffrey S, Trichopoulos Dimitrios, Virtamo Jarmo, Visvanathan Kala, Wactawski-Wende Jean, Wang Chengfeng, Yu Kai, Zeleniuch-Jacquotte Anne, Chanock Stephen, Hoover Robert, Hartge Patricia, Fuchs Charles S, Lin Dongxin, Wolpin Brian M
Abstract excerpt
BACKGROUND AND OBJECTIVE: Survival of patients with pancreatic adenocarcinoma is limited and few prognostic factors are known. We conducted a two-stage genome-wide association study (GWAS) to identify germline variants associated with survival in patients with pancreatic adenocarcinoma. METHODS: We analysed overall survival in relation to single nucleotide polymorphisms (SNPs) among 1005 patients from two large...
Read the complete abstract on PubMed